In brief
- FDA issued a June 23, 2026 letter to LyfeUnit about unapproved ketamine products and sales without requiring prescription. This letter does not verify the earlier count of fifteen sellers.
- The letter cites ketamine vials marketed by LyfeUnit as an example; an inventory of every other seller’s formulations is not established here.
- FDA warns of possible contamination and other risks. Ketamine has approved anesthetic uses; esketamine is a derivative with psychiatric indications and its own safeguards.
In its June 23, 2026 letter, FDA documents that LyfeUnit offered a ketamine product not approved in the United States without requiring prescription. These are findings attributed to the agency, not a court judgment. The total of fifteen sellers, their geographic distribution and the claim of a largest-ever operation are not ratified here.
What the LyfeUnit letter establishes
The inspected letter concerns LyfeUnit and gives Rotexmedica vials as an example. FDA considers the product’s claims and marketing to make it an unapproved and misbranded drug under US law. This review is not extrapolated to every product, consultation or seller mentioned elsewhere.
Risks identified by the agency
FDA identifies risks of unapproved products: possible contamination, counterfeiting or different ingredients and quantities from those declared. For injectables it mentions the possibility of sepsis; it does not provide vial-by-vial testing or document an outbreak here. It distinguishes approved anesthetic ketamine from esketamine nasal spray Spravato, a derivative with specific psychiatric indications. The letter describes boxed warnings and a restricted REMS program with supervised administration and monitoring for at least two hours. Approval does not mean absence of risk.
What this implies
The letter is a regulatory action concerning products and sales, not a ketamine efficacy trial or a causal analysis of informal markets. FDA’s risk description does not certify every product’s composition or establish composition as the sole or main harm in every context. For general information, consult our harm reduction guide; the letter requests a response within fifteen business days of receipt and warns of possible further action. Later compliance by the recipient is not certified. Also consult our ketamine pillar.
Source
- FDA. Warning Letter: LyfeUnit / www.lyfeunit.com. U.S. Food and Drug Administration, June 23, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
